文献速递产科母胎医学

慢性高血压与重叠子痫前期:筛查和诊断

Chronic hypertension and superimposed preeclampsia: screening and diagnosis.
PubMed 文献 · Am J Obstet Gynecol · 2021-06-17

本文综述了慢性高血压孕妇中重叠子痫前期的诊断标准与潜在生物标志物证据。重叠子痫前期约占慢性高血压孕妇的20%,因传统诊断标准常先于妊娠存在而难以鉴别。尿酸、肾素-血管紧张素醛固酮系统、血管生成因子、炎症介质及pro-B型利钠肽等标志物的区分度均有限,现有证据尚不支持临床用于风险分层。

要点

  • 重叠子痫前期约占慢性高血压孕妇的20%,母儿病率高于单纯子痫前期。
  • 慢性高血压孕妇的血管生成因子水平本身已受损,其预测重叠子痫前期的区分度低于一般产科人群。
  • 现有有限证据提示炎症介质和pro-B型利钠肽等标志物的差异幅度 modest,尚不能用于临床风险分层。

核心结论

  • 慢性高血压孕妇中重叠子痫前期的诊断面临挑战,传统标准常先于妊娠存在。
  • 现有潜在生物标志物对重叠子痫前期的预测或区分能力均有限,尚不支持临床用于风险分层。

研究设计与样本

  • 本文为综述,讨论重叠子痫前期的当前诊断标准并总结潜在生物标志物的证据。

主要发现

  • 重叠子痫前期约占慢性高血压孕妇妊娠的20%,并与较单纯子痫前期更高的母儿病率相关。
  • 尿酸升高及肾素-血管紧张素醛固酮系统等肾脏标志物受抑制在重叠子痫前期孕妇中可见,但预测能力仅为中等。
  • 可溶性fms样酪氨酸激酶-1和胎盘生长因子在慢性高血压孕妇中无论是否发生重叠子痫前期均已受损,故其水平差异的区分度低于一般产科人群。
  • 肿瘤坏死因子-α、白细胞介素-6、细胞黏附分子及内皮素等促炎介质在重叠子痫前期筛查和诊断中的作用已有研究,现有有限证据提示差异幅度也为中等且不具备临床实用性。
  • 重叠子痫前期孕妇的pro-B型利钠肽水平高于未发生者,但当前证据提示pro-B型利钠肽不是该病的预测因子。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 现有证据有限,炎症介质等标志物的差异幅度为中等且不具备临床实用性。
  • 当前证据提示pro-B型利钠肽不是重叠子痫前期的预测因子。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Superimposed preeclampsia complicates about 20% of pregnancies in women with chronic hypertension and is associated with increased maternal and perinatal morbidity compared with preeclampsia alone. Distinguishing superimposed preeclampsia from chronic hypertension can be challenging because, in chronic hypertension, the traditional criteria for the diagnosis of preeclampsia, hypertension, and significant proteinuria can often predate the pregnancy. Furthermore, the prevalence of superimposed preeclampsia is unlikely to be uniformly distributed across this high-risk group but is related to the severity of preexisting endothelial dysfunction. This has led to interest in identifying biomarkers that could help in screening and diagnosis of superimposed preeclampsia and in the stratification of risk in women with chronic hypertension. Elevated levels of uric acid and suppression of other renal biomarkers, such as the renin-angiotensin aldosterone system, have been demonstrated in women with superimposed preeclampsia but perform only modestly in its prediction. In addition, central to the pathogenesis of preeclampsia is a tendency toward an antiangiogenic state thought to be triggered by an impaired placenta and, ultimately, contributing to the endothelial dysfunction pathognomonic of the disease. In the general obstetrical population, angiogenic factors, such as soluble fms-like tyrosine kinase-1 and placental growth factor, have shown promise in the prediction of preeclampsia. However, soluble fms-like tyrosine kinase-1 and placental growth factor are impaired in women with chronic hypertension irrespective of whether they develop superimposed preeclampsia. Therefore, the differences in levels are less discriminatory in the prediction of superimposed preeclampsia compared with the general obstetrical population. Alternative biomarkers to the angiogenic and renal factors include those of endothelial dysfunction. A characteristic of both preeclampsia and chronic hypertension is an exaggerated systemic inflammatory response causing or augmenting endothelial dysfunction. Thus, proinflammatory mediators, such as tumor necrosis factor-α, interleukin-6, cell adhesion molecules, and endothelin, have been investigated for their role in the screening and diagnosis of superimposed preeclampsia in women with chronic hypertension. To date, the existing limited evidence suggests that the differences between those who develop superimposed preeclampsia and those who do not are, as with angiogenic factors, also modest and not clinically useful for the stratification of women with chronic hypertension. Finally, pro-B-type natriuretic peptide is regarded as a sensitive marker of early cardiac dysfunction that, in women with chronic hypertension, may predate the pregnancy. Thus, it has been proposed that pro-B-type natriuretic peptide could give insight as to the ability of women with chronic hypertension to adapt to the hemodynamic requirements of pregnancy and, subsequently, their risk of developing superimposed preeclampsia. Although higher levels of pro-B-type natriuretic peptide have been demonstrated in women with superimposed preeclampsia compared with those without, current evidence suggests that pro-B-type natriuretic peptide is not a predictor for the disease. The objectives of this review are to, first, discuss the current criteria for the diagnosis of superimposed preeclampsia and, second, to summarize the evidence for these potential biomarkers that may assist in the diagnosis of superimposed preeclampsia.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Kametas NA, Nzelu D, Nicolaides KH, et al. Chronic hypertension and superimposed preeclampsia: screening and diagnosis. Am J Obstet Gynecol. 2021. PMID: 35177217. doi:10.1016/j.ajog.2020.11.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。